People with lupus often need to use medicines to manage their symptoms. Although there are many oral medicines that treat lupus, some people with more severe symptoms may not get enough benefit from ...

Benlysta is a human monoclonal antibody that was approved for the treatment of lupus in adults by the U.S. Food and Drug Administration (FDA) in 2011 and for lupus nephritis in adults in 2020.

Please provide your email address to receive an email when new articles are posted on . The FDA approved a 200 mg Benlysta autoinjector for children aged 5 years and ...

Benlysta (belimumab) is a biologic developed by Human Genome Sciences in partnership with GlaxoSmithKline (GSK). A biologic is a large, complex molecule that is produced using recombinant DNA ...

MONDAY, June 30, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved an autoinjector of Benlysta (belimumab) for subcutaneous injection in patients ≥5 years of age with active ...

The 200mg single-dose prefilled autoinjector allows pediatric patients to receive SLE treatment at home via SC administration. The Food and Drug Administration (FDA) has approved Benlysta (belimumab) ...

The approval makes belimumab (Benlysta) the first at-home treatment in its class for patients 5 years and older with systemic lupus erythematosus (SLE). The FDA approved GSK’s belimumab (Benlysta) ...

Boeing last month announced a new delay for its largest twin-engine plane.

The FDA approved a 200 mg/mL belimumab autoinjector for pediatric lupus nephritis, enabling at-home administration and reducing clinic visits. Lupus nephritis affects 30-50% of children with SLE, ...

Benlysta is an immunosuppressant medication that can lower the amount of antibodies your immune system produces. This makes it effective in managing different forms of lupus. Benlysta works by ...